Rheumatology News This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 28.

Regeneron Provides Update On FDA Advisory Committee Discussion Of ARCALYST® (rilonacept) Injection
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against approval of ARCALYST® (rilonacept) Injection for Subcutaneous Use for the proposed indication for the prevention of gout flares in patients initiating uric acid-lowering therapy.
Source: Pharmaceutical Online News - May 11, 2012 Category: Pharmaceuticals Source Type: news

Study compares infection risk for JIA, ADHD patients
Children with juvenile idiopathic arthritis were at twice the risk of infection compared with children with attention-deficit hyperactivity disorder, according to a study published May 1 in Arthritis & Rheumatism.
Source: Modern Medicine - May 11, 2012 Category: Journals (General) Source Type: news

Biologics no better than DMARDs for refractory RA
Biologic treatment offers little long-term clinical benefit over conventional treatment for patients with rheumatoid arthritis who fail to respond to initial methotrexate therapy, Swedish researchers report.
Source: MedWire News - Bone Health - May 10, 2012 Category: Orthopaedics Source Type: news

Lack of research undermines GP diagnosis of polymyalgia
Early diagnosis of the most common inflammatory rheumatic disorder seen by GPs is being hindered by a lack of primary care research, an expert has warned.
Source: HealthcareRepublic Pharmacist News - May 10, 2012 Category: Primary Care Source Type: news

Pfizer’s Rheumatoid Arthritis Pill Wins Federal Panel’s Approval
A federal advisory panel recommended approval of a rheumatoid arthritis pill known as tofacitinib, but several members expressed concern about its safety.
Source: NYT - May 10, 2012 Category: American Health Authors: By KATIE THOMAS Tags: Drugs (Pharmaceuticals) Rheumatoid Arthritis Accidents and Safety Food and Drug Administration Pfizer Inc PFE NYSE Source Type: news

Health Highlights: May 10, 2012
Words in Larger Fonts Cause Stronger Reaction: Study Common Bacteria Caused Flesh-Eating Disease in Georgia Woman Washington State Declares Whooping Cough Epidemic Pool Water Slides Recalled After Death, Serious Injuries Report Shows Questionable Billing by Thousands of U.S. Pharmacies FDA Should OK New Rheumatoid Arthritis Pill: Panel FDA Questions Long-Term Benefits of Bone Drugs
Source: The Doctors Lounge - Health News - May 10, 2012 Category: Consumer Health News Authors: webmaster at doctorslounge.com Tags: Family Medicine, WebScout, Source Type: news

Health Tip: When Your Knee is Unstable
Here are potential warning signs
Source: Rheumatology News - Doctors Lounge - May 10, 2012 Category: Rheumatology Authors: webmaster at doctorslounge.com Tags: Rheumatology, FYI, Source Type: news

Roche conference call for investors and analysts from EULAR 2012
ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with Actemra compared to adalimumab - Friday, 8 June 2012, Berlin, Germany. We kindly invite investors and analysts to participate in a conference call that will be held during the EULAR Annual European Congress of Rheumatology from 6 - 9 June 2012 in Berlin. On the call, Roche will discuss new data from ADACTA, the first study that was specifically designed to determine superiority between two approved biologic therapies for the treatment of rheumatoid arthritis in the monotherapy setting.
Source: Roche Investor Update - May 10, 2012 Category: Pharmaceuticals Source Type: news

Strides Made in Diagnosing, Treating Lupus
Title: Strides Made in Diagnosing, Treating LupusCategory: Health NewsCreated: 5/10/2012 10:05:00 AMLast Editorial Review: 5/10/2012 12:00:00 AM
Source: MedicineNet Arthritis General - May 10, 2012 Category: Rheumatology Source Type: news

Scleroderma Complications Worse in Blacks Than Whites: Study
Title: Scleroderma Complications Worse in Blacks Than Whites: StudyCategory: Health NewsCreated: 5/10/2012 10:05:00 AMLast Editorial Review: 5/10/2012 12:00:00 AM
Source: MedicineNet Arthritis General - May 10, 2012 Category: Rheumatology Source Type: news

New screening technique yields elusive compounds to block immune-regulating enzyme
(Scripps Research Institute) Scientists at the Scripps Research Institute have found the first chemical compounds that act to block an enzyme that has been linked to inflammatory conditions such as asthma and arthritis, as well as some inflammation-promoted cancers.
Source: EurekAlert! - Biology - May 10, 2012 Category: Biology Source Type: news

Study compares infection risk for JIA, ADHD patients
Children with juvenile idiopathic arthritis were at twice the risk of infection compared with children with attention-deficit hyperactivity disorder, according to a study published May 1 in Arthritis & Rheumatism.
Source: Drug Topics - Pharmacy News - May 10, 2012 Category: Pharmaceuticals Source Type: news

Horizon scanning: FDA advisory panel recommends approval of tofacitinib for adult patients with moderately to severely active rheumatoid arthritis
Source: PharmaLive Area: News An FDA advisory panel has recommended the approval of investigational agent tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). If approved by the Agency, tofacitinib would be the first new oral DMARD for RA in more than 10 years and the first RA treatment in a new class of medicines known as Janus kinase (JAK) inhibitors. Unlike more recent therapies for RA, which are directed at extracellular targets such as pro-inflammatory cytokines, tofacitinib targets the intracellular pathways that operate as hubs in the inflammatory cytokine ne...
Source: NeLM - News - May 10, 2012 Category: Drugs & Pharmacology Source Type: news

Study compares infection risk for JIA, ADHD patients
Children with juvenile idiopathic arthritis were at twice the risk of infection compared with children with attention-deficit hyperactivity disorder, according to a study published May 1 in Arthritis & Rheumatism.
Source: Drug Topics - Clinical News - May 10, 2012 Category: Drugs & Pharmacology Source Type: news

Strides Made in Diagnosing, Treating Lupus
New therapies are being developed for people with the autoimmune illness, experts say
Source: The Doctors Lounge - Infections - May 10, 2012 Category: Infectious Diseases Authors: webmaster at doctorslounge.com Tags: Dermatology, Family Medicine, Infections, Pharmacy, Rheumatology, Sports Medicine, Immunology, Nutrition, News, Source Type: news

Depression and RA
Depression and rheumatoid arthritis often occur together. Those with depression and rheumatoid arthritis also seem to have more severe arthritis symptoms and pain.
Source: About.com Eating Disorders - May 10, 2012 Category: Eating Disorders and Weight Management Authors: depression.guide at about.com Tags: health Source Type: news

Don't Ignore Arthritis Signs
Arthritis signs should not be ignored. Consult with a doctor so that you can get an accurate diagnosis and appropriate treatment.
Source: About.com Eating Disorders - May 10, 2012 Category: Eating Disorders and Weight Management Authors: depression.guide at about.com Tags: health Source Type: news

Culprit responsible for severe systemic scleroderma complications in African-Americans found
(Georgetown University Medical Center) A new analysis finds that compared to Caucasians, African-Americans with systemic scleroderma have more antibodies in the blood that are linked to severe complications and an increased likelihood of death. They say this finding, published today in Arthritis & Rheumatism, suggests physicians can use these disease markers to screen and treat scleroderma patients proactively.
Source: EurekAlert! - Biology - May 10, 2012 Category: Biology Source Type: news

Study compares risk for JIA, ADHD patients
Children with juvenile idiopathic arthritis were at twice the risk of infection compared with children with attention-deficit hyperactivity disorder, according to a study published May 1 in Arthritis & Rheumatism.
Source: Drug Topics - Pharmacy News - May 10, 2012 Category: Pharmaceuticals Source Type: news

Chronic Disease Tops Infection as Global Issue
(MedPage Today) -- An increasing number of people in low- to middle-income countries are now dealing with hypertension and arthritis, according to a new global report.
Source: MedPage Today Public Health - May 9, 2012 Category: American Health Source Type: news

FDA Weighs In On Gilead's Crucial Pill
During a tremendously busy week for the Food and Drug Administration and the drug business, all eyes are on the FDA advisory panel for Pfizer's rheumatoid arthritis drug tofacitinib today (the panel voted the drug should be approved) and Arena Pharmaceuticals' weight loss medicine lorcaserin tomorrow. But another key medicine goes up for review on Friday: the so called "Quad" pill from Gilead, to treat HIV.
Source: Forbes.com Healthcare News - May 9, 2012 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

Oral Arthritis Drug Gets Nod from FDA Panel
(MedPage Today) -- SILVER SPRING, Md. -- An FDA advisory committee has voted 8-2 in favor of recommending approval of the oral JAK inhibitor tofacitinib for the treatment of rheumatoid arthritis.
Source: MedPage Today Rheumatology - May 9, 2012 Category: Rheumatology Source Type: news

Pfizer's Arthritis Pill Gets Nod from FDA Panel
(MedPage Today) -- SILVER SPRING, Md. -- An FDA advisory committee has voted 8-2 in favor of recommending approval of the oral JAK inhibitor tofacitinib for the treatment of rheumatoid arthritis.
Source: MedPage Today Public Health - May 9, 2012 Category: American Health Source Type: news

FDA Arthritis Advisory Committee Recommends Approval of Tofacitinib for Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
NEW YORK--(BUSINESS WIRE)--May 9, 2012 - Pfizer Inc. announced today that the Arthritis Advisory Committee to the U.S. Food and Drug Administration (FDA) voted 8-2 to recommend approval of the investigational agent tofacitinib for the treatment of...
Source: Drugs.com - New Drug Applications - May 9, 2012 Category: Drugs & Pharmacology Source Type: news

Arthritic Pain, Nerve Sprouting and Neuroma Formation
Our friends, Drs Mantyh and Jimenez Andrade, have published important findings on the potential root cuases of age related Arthritic Pain: Juan M Jimenez-Andrade and Patrick W Mantyh. Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice. Note: our Chicken Polyclonal NF200 Antibody was used to label primary afferent sensory nerve fibers.Overview: Introduction: Although the prevalence of arthritis dramatically increases with age, the great majority of preclinical studies concerning the mechanisms that drive arthritic joint pain have been perfo...
Source: Neuromics - May 9, 2012 Category: Neuroscience Tags: Neurofilament-H Antibody Arthritis Neuroma Arthritic Pain CGRP antibody Arthritic Joints Nerve Sprouting afferent sensory nerve fibers. NF200 antibody Source Type: news

Arthritis sufferers have to wait THREE YEARS to be diagnosed condemning them to 'unbearable pain'
More than a quarter of arthritis sufferers in the UK have to visit their GP at least three times to get a diagnosis, a report by Arthritis Care revealed today.
Source: the Mail online | Health - May 9, 2012 Category: Consumer Health News Source Type: news

Tissue engineering expert elected as leader of international scientific society
Anthony Hollander, ARC Professor of Rheumatology and Tissue Engineering at the University of Bristol has been elected President of the International Cartilage Repair Society (ICRS).
Source: University of Bristol news - May 9, 2012 Category: Universities & Medical Training Authors: news_text Tags: Press releases Source Type: news

U.S. FDA advisers back Pfizer arthritis drug
WASHINGTON (Reuters) - Pfizer Inc won a U.S. advisory panel's support on Wednesday for its arthritis drug tofacitinib.
Source: Modern Medicine - May 9, 2012 Category: Journals (General) Source Type: news

New Horizons for Treatment of ANCA-associated VasculitidesNew Horizons for Treatment of ANCA-associated Vasculitides
Should rituximab be the first-line drug combined with glucocorticoids for ANCA-associated vasculitides? Rheumatology
Source: Medscape Rheumatology Headlines - May 8, 2012 Category: Rheumatology Tags: Rheumatology Journal Article Source Type: news

Data Inconclusive for Oral Arthritis Drug
WASHINGTON (MedPage Today) -- FDA reviewers were unable to draw definite conclusions about tofacitinib's ability to prevent progression of structural damage in rheumatoid arthritis and had questions about increased risks with the drug.
Source: MedPage Today Rheumatology - May 8, 2012 Category: Rheumatology Source Type: news

Humira Could Have Been a Pfizer Drug
Lipitor has long dominated the list of the top selling drugs annually. However, with the expiration of the patent for the active ingredient of Lipitor, atorvastatin, at the end of 2011, there is a new king of the hill. According to a Reuters article (April 4th) entitled “Abbott drug tops sales as Lipitor, Plavix era ends," the new leader is an antibody named Humira. Initially developed as a treatment for rheumatoid arthritis (RA), this antibody blocks the effects of TNF-alpha and, in doing so, reduces the production of inflammatory mediators that damage the joints of RA patients. The history of th...
Source: Forbes.com Healthcare News - May 8, 2012 Category: Pharmaceuticals Authors: John LaMattina Source Type: news

F.D.A. Staff Raises Concerns About Arthritis Drug
As an advisory panel prepared to consider whether to recommend federal approval of Pfizer’s rheumatoid arthritis pill, F.D.A. documents raise safety questions.
Source: NYT - May 8, 2012 Category: American Health Authors: By KATIE THOMAS Tags: Drugs (Pharmaceuticals) Arthritis Rheumatoid Arthritis Pfizer Inc PFE NYSE Food and Drug Administration Source Type: news

Best of Medical Blogs - weekly review, blog carnival
The “Best of Medical Blogs - weekly review, blog carnival” is a weekly summary of the best posts from medical blogs. Feel free to send your suggestions to my email at clinicalcases@gmail.com. Best of Medical Blogs is published every Tuesday, just like the old Grand Rounds. Social Networks for Doctors: Are We There, Yet? Twitter can be as inane, or as useful, as the accounts you follow. Sure, doctors use Facebook like everyone else, but – by and large – they haven’t tapped into the educational potential that online social networks offer. Once viewed as a trivial hobby by more eminent researchers and w...
Source: Clinical Cases and Images - May 8, 2012 Category: Journals (General) Tags: Best of Medical Blogs Source Type: news

Could copper be the answer to arthritis?
FOR centuries copper has been used in alternative medicine to relieve the pain of arthritis and joint conditions but until recently there was little scientific evidence to prove it actually works. Could that be about to change?
Source: Daily Express - Health - May 7, 2012 Category: Consumer Health News Source Type: news

Pfizer Rheumatoid Arthritis Pill Looks 'Approvable'
Will the Pfizer pill for rheumatoid arthritis – the first oral biologic for treating this ailment – pass muster with the FDA? Wall Street continues to bet its drug will win approval, but agency briefing documents released in advance of an advisory panel meeting this week raise raise some tough questions about what the drugmaker hopes will become a blockbuster medicine.
Source: Forbes.com Healthcare News - May 7, 2012 Category: Pharmaceuticals Authors: Ed Silverman Source Type: news

10 Ways to Manage Low Back Pain at Home
Title: 10 Ways to Manage Low Back Pain at HomeCategory: Health FactsCreated: 5/16/2012 7:51:00 PMLast Editorial Review: 5/7/2012 7:51:29 PM
Source: MedicineNet Arthritis General - May 7, 2012 Category: Rheumatology Source Type: news

Rising Obesity Rates Might Mean More Rheumatoid Arthritis
Title: Rising Obesity Rates Might Mean More Rheumatoid ArthritisCategory: Health NewsCreated: 5/4/2012 4:05:00 PMLast Editorial Review: 5/7/2012 12:00:00 AM
Source: MedicineNet Arthritis General - May 7, 2012 Category: Rheumatology Source Type: news

Arthritis Medications - Test Your Knowledge
Several arthritis medications have been marketed since 1998. How much do you know about arthritis medications? Take the quiz.
Source: About.com Eating Disorders - May 5, 2012 Category: Eating Disorders and Weight Management Authors: highbloodpressure.guide at about.com Tags: health Source Type: news

Lupus Nephritis: First ACR Guidelines PublishedLupus Nephritis: First ACR Guidelines Published
The American College of Rheumatology has issued the first-ever guidelines for the diagnosis and treatment of lupus nephritis, including recommendations for both long-term and short-term care. Medscape Medical News
Source: Medscape Nephrology Headlines - May 4, 2012 Category: Urology & Nephrology Tags: Rheumatology News Source Type: news

ACR Issues Lupus Nephritis Tx Guideline (CME/CE)
(MedPage Today) -- Management guidelines for patients with lupus nephritis, including a detailed treatment algorithm for patients with moderate disease, have been released by the American College of Rheumatology.
Source: MedPage Today Primary Care - May 4, 2012 Category: Primary Care Source Type: news

Death Rate Still High in RA Vasculitis (CME/CE)
GLASGOW (MedPage Today) -- The incidence of systemic rheumatoid vasculitis decreased in the era of modern immunosuppressive therapy, but mortality remains pronounced, a researcher reported here.
Source: MedPage Today Geriatrics - May 4, 2012 Category: Geriatrics Source Type: news

RA Found Sooner Using Newest Disease Criteria (CME/CE)
GLASGOW (MedPage Today) -- The recently revised rheumatoid arthritis classification criteria successfully identified affected patients in the U.K. earlier than the previous set of criteria, a researcher reported here.
Source: MedPage Today Geriatrics - May 4, 2012 Category: Geriatrics Source Type: news

IL-17 Antibody May Have Role in Arthritis (CME/CE)
GLASGOW (MedPage Today) -- The investigative anti-IL-17 monoclonal antibody secukinumab may prove effective in the treatment of rheumatoid arthritis patients who do not respond to tumor necrosis factor inhibitors, a researcher said here.
Source: MedPage Today Geriatrics - May 4, 2012 Category: Geriatrics Source Type: news

Rising Obesity Rates Might Mean More Rheumatoid Arthritis
Researchers suggest weight gain precedes the painful condition
Source: The Doctors Lounge - Health News - May 4, 2012 Category: Consumer Health News Authors: webmaster at doctorslounge.com Tags: Family Medicine, Rheumatology, Nutrition, News, Source Type: news

IL-6 Antibody Works in Arthritic Kids (CME/CE)
GLASGOW (MedPage Today) -- Tocilizumab (Actemra) has maintained durable efficacy for children with systemic juvenile idiopathic arthritis in an open-label extension study, researchers reported here.
Source: MedPage Today Meeting Coverage - May 4, 2012 Category: Journals (General) Source Type: news